This Biopharmaceutical Stock Could Triple From Current Levels

The biopharmaceutical stock discussed in today’s article could triple from current levels if the positive thesis of one analyst covering the stock plays out – and the rest of Wall Street seems equally bullish on the stock, with a “Strong Buy” consensus rating. For more on this biopharma company, which is focused on the development and commercialization of novel medicines for patients affected by central nervous system disorders, and the positive thesis for its stock, CLICK HERE.